Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and renal disease as assessed by Steno Risk Engines in adults with type 1 diabetes
Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
| Original language | English |
|---|---|
| Journal | Diabetologia |
| Volume | 65 |
| Issue number | SUPPL 1 |
| Pages (from-to) | S47 |
| Number of pages | 1 |
| ISSN | 0012-186X |
| Publication status | Published - 2022 |
ID: 318157773